Duesseldorf – An international and mul­tidiscip­lin­ary CMS team has advised a consortium of Swiss Life Asset Managers, on behalf of their infrastructure funds, and Vesper Next Generation Infrastructure Fund I SCSp on the acquisition of all shares in RAD-x SAS, a leading Pan-European diagnostic imaging platform, from private equity investor Gilde Healthcare. RAD-x is one of the leading diagnostic imaging providers in Germany and Switzerland. Through its continued focus on technology and innovation, RAD-x remains at the forefront of diagnostic imaging as it provides high quality and reliable diagnostic services to its patients. Established in 2011, the Swiss Life Asset Managers Infrastructure Equity platform manages over EUR 10bn in Assets under Management for its clients and partners, and includes 75 infrastructure investments across the energy, communications, transportation, regulated utilities, social infrastructure and renewable energy sectors. Vesper Infrastructure Partners’ Next Generation Infrastructure Fund I is a closed-end alternative investment fund based in Luxembourg managed by Sanne LIS, which pursues infrastructure investment opportunities, including healthy living solutions. CMS Germany Dr Sebastian Becker, Partner Ole Gunnar Weyand, Senior Associate Nina Becker, As­so­ci­ate Car­oline Rolf, Associate Greta Ludewig, Associate, all Private Equity/M&A Dr Martin Friedberg, Partner Dr Hendrik Arendt, Senior Associate, both Tax Dr Angela Emmert, Partner Lennard Lürwer, Counsel Daniel Hennig, Counsel Dr Mario Brungs, Counsel Dr Yannick Schmitter, Associate, all Employment Law Dr Andreas Hofelich, Partner, Pensions Dr André Frischemeier, Partner Thomas Schaak, Senior Associate Dr Dirk Schmidbauer, Associate, all Finance Kai Neuhaus, Partner Dr Björn Herbers, Partner Moritz Pottek, Counsel David Rappenglück, Associate, all Antitrust and Foreign Investment Control Dr Roland Wiring, Partner Philippe Heinzke, Partner Dr Siham Hidar, Senior As­so­ci­ate Se­basti­an Vautz, Senior Associate Noah Rodenkirchen, Associate, all IP Maike Füchtmann, Senior Associate, Real Estate & Public CMS UK Narinder Jugpal, Partner Ben Mc­Par­land Jen­nifer Ross, all Private Equity/M&A Patrick Donegan, Partner Andreas Göller, both Finance CMS France Thomas Hains, Part­ner Anne-Flore Millet Louise Paysant CMS Switzerland Stephan Werlen, Part­ner Ferdin­and BlezingerPress Con­tact presse@cms-hs. com

Frankfurt/Main – QUARTERBACK Immobilien AG has entered into a EUR 125 million credit agreement with Deutsche Bank AG. The agreed loan will be used for acquiring renewable energy projects at an advanced stage of development, with a focus on solar. This will support the expansion of QUARTERBACK’s renewable energy business. The credit line will enable the energy developer to rapidly progress solar projects with power generation potential totalling around two gigawatts. These projects will then be sold to institutional equity investors. The initial funding has already been paid out and allocated.A CMS team headed by lead partner Dr Markus Pfaff advised QUARTERBACK on all legal aspects of the project financing. Leipzig-based QUARTERBACK Immobilien AG specialises in project development and realisation, property maintenance, portfolio expansion, administration and facility management. In the renewable energy space, the company develops large-scale solar plants for institutional investors, energy service providers and for its own power generation needs. It currently has a pipeline of around five gigawatts. CMS partner Dr Jochen Lux has been advising the QUARTERBACK Group for some time now on the acquisition and sale of development projects involving real estate and new energy. CMS Germany Dr Markus Pfaff, Lead Partner Dr André Frischemeier, Partner Hatice Akyel, Counsel Thomas Schaak, Senior Associate, all Banking & FinancePress Con­tact presse@cms-hs. com

Frankfurt/Main – Bruker has agreed to acquire ELITechGroup, a provider of specialty in vitro diagnostic (IVD) systems, from TecFin S.à r.l., a controlled affiliate of PAI Partners, a pre-eminent private equity firm, for EUR 870 million in cash, excluding the carved out ELITech clinical chemistry business. The transaction is expected to close in the second quarter of 2024, subject to regulatory approvals and other customary closing conditions.A team of CMS Germany headed by lead partner Dr Hendrik Hirsch acted as lead transaction counsel on this landmark transaction for Bruker's MDx business covering all M&A aspects of the transaction, IVDR and other regulatory aspects, antitrust and FDI filings, the carve out of the clinical chemistry business and support on the employee consultation processes in France and the Netherlands. ELITechGroup, with over 500 employees and over 40 active patents, develops and commercializes innovative, proprietary molecular diagnostic (MDx) systems and assays, as well as niche biomedical systems and microbiology products. Its molecular diagnostic business accounts for the majority of the to-be-acquired revenues and provides the unique sample-to-answer (S2A) instruments InGenius® and Be-Genius® in the mid-to-high throughput MDx category with PCR diagnostic assays for infections and diseases. ELITechGroup, excluding the clinical chemistry business, achieved approximately EUR 150 million in revenues in 2023. ELITechGroup generates the majority of its revenues from Europe, with significant business also in North and Latin America. Its major R&D and production sites are in Italy, the United States, France and Germany. CMS Germany Dr Hendrik Hirsch, Partner, Co-Lead Dr Jacob Siebert, Partner, Co-Lead Dr Dirk Baukholt, Principal Counsel Dr Berrit Roth-Mingram, Counsel Dr Maximilian Stark, Senior Associate, all Corporate/M&A Dr Roland Wiring, Partner Lukas Burgdorff, Associate Noah Rodenkirchen, Associate, all Regulatory & Lifesciences Dr Thomas Hirse, Part­ner Se­basti­an Vautz, Senior Associate Lisa Dietrich, Associate, all IP Dr Michael Bauer, Partner Stefan Lehr, Partner Kai Neuhaus, Partner Moritz Pottek, Counsel Dr. Denis Schlimpert, Counsel Kirsten Baubkus-Gerard, Senior Associate David Rappenglück, As­so­ci­ate Be­ne­dikt Christian Voss, Associate, all Antitrust, Competition & Trade Dr Thomas de la Motte, Partner Dr Markus Pfaff, Partner Dr André Frischemeier, Partner Hatice Aykel, Counsel Alisa Brehm, Senior Associate Thomas Schaak, Senior Associate Dr Sait Dogan, Associate, all Banking & Finance  Dr André Lippert, Part­ner Con­stan­ze Schweidtmann, Associate, both Real Estate & Public Dr Boris Alles, Partner Dr Theresa Kipp, Senior Associate, both Labor, Employment & Pensions CMS France Benoît Gomel, Partner Vincent Desbenoit, Associate Dylan Allali, all Corporate/M&A Caroline Froger-Michon, Partner Aurélie Parchet, As­so­ci­ate Ca­m­ille Baumgarten, Associate Sophie Yin, all Em­ploy­ment Claire Vannini, Partner Eleni Moraïtou, Coun­sel Lilia-Ori­ana Dif, Associate Ariane Rolin, all Competition & EU  Jean-Bap­tiste Thiénot, Partner Anaïs Arnal, Associate, both Intellectual Property Laurine Mayer, Associate, TMC Alexandre Chazot, Counsel, Banking & Fin­ance  Thi­erry Granier, Partner Renaud Grob, Partner, both Tax Arnaud Valverde, Senior Associate, Real Estate Olivier Kuhn, Partner Cécile Rebiffé, Counsel Mylène Garrouste, all Dispute Res­ol­u­tion Kawthar Ben Khelil, Coun­sel Jean-Pierre Malili, Associate, both Public law/In­fra­struc­ture CMS Italy Massimo Trentino, Partner, Corporate/M&A Maria Letizia Patania, Partner, Lifescience & Healthcare Gian Marco Lettieri, Senior Associate, Employment & Pensions Giulio Poggioli, Counsel Valerio Giuseppe Daniele, As­so­ci­ate Francesca Durante, Junior As­so­ci­ate  Arianna Toccaceli, Junior Associate, all Banking & Finance CMS Luxembourg Gérard Maitrejean, Partner Miruna Poenaru, Coun­sel Max­imili­an Helfgen, Associate, all Corporate/M&A CMS UK Jack Letson, Partner Lindsay McAllister, Associate, both Corporate/M&A David Dennis, Partner, Commercial CMS Netherlands Pieter van Duijvenvoorde, Partner Robert Jong, both Corporate/M&A Nigel Henssen Fleur van Assendelft de Coningh, both Employment Edmon Oude Elferink, Partner Marijke van der Vossen, both Antitrust, Competition & Trade CMS Serbia Radivoje Petrikić, Partner Mila Drljević, both Corporate/M&A CMS Austria Dieter Zandler, Partner Vanessa Horaceck, both Competition & EU CMS Ukraine Maria Orlyk, Partner Diana Valyeyeva CMS Turkiye Döne Yalçın, Partner Arcan Kemahlı,  Sa­ba­hat­tin Öztemiz Taner ElmasPress Con­tact presse@cms-hs. com

Frankfurt/Main – Funds advised by DPE Deutsche Private Equity have sold the VTU Group to Altor Funds, with the VTU management team likewise selling its interest in the company. DPE is an independent...

Frankfurt/Main – The shareholders of M.M. Warburg & CO Hypothekenbank AG, namely M.M. Warburg & CO (AG & Co.) KGaA (60%) and Landeskranken­hil­fe V.V.a.G. (40%), have sold all their shares in Warburg...